Introduction: About 8% of children born small for gestational age (SGA) do not reach a final height within the normal range. Recombinant human growth hormone (rhGH) has been shown to be effective in increasing the final height in children born SGA. Our objective was to identify predictive factors of final height in children born SGA treated with rhGH. Materials and Methods: In this retrospective study, conducted in a tertiary pediatric endocrinology referral center, we recruited all patients born SGA (defined as birth length or weight #x3c;10th percentile) treated with rhGH for more than 12 months for whom final height data were available. Some patients had received gonadotropin-releasing hormone (GnRH) analog therapy. Results: We included 252 patients with an average birth length of −2.0 ± 0.7 SD and birth weight of −1.7 ± 1.0 SD. After 4.6 ± 2.8 years of rhGH treatment, their height increased from −2.2 ± 0.9 SD to −1.5 ± 0.9 SD. In multivariate analysis, we identified 8 factors that predict 46% of the final height, namely, cause of SGA (p #x3c; 0.0001), GnRH analog therapy #x3e;2 years (p = 0.006), birth length (p #x3c; 0.02), height at the start of rhGH (p #x3c; 0.0001), IGF-1 level at the start of rhGH (p = 0.0002), growth velocity during the 1st year of treatment (p = 0.0002), and age and height at the onset of puberty (p #x3c; 0.0001, p = 0.0007, respectively). Conclusion: In this large cohort of SGA patients who had reached their final height, we were able to confirm that growth hormone increases final height in short SGA children. In addition, we identified several factors associated with a better response to growth hormone treatment.
Horm Res Paediatr

中文翻译：

---

接受重组生长激素治疗的小于胎龄儿的最终身高的决定因素

简介：大约 8% 的出生小于胎龄 (SGA) 的儿童最终身高未达到正常范围内。重组人生长激素 (rhGH) 已被证明可有效增加出生 SGA 儿童的最终身高。我们的目标是确定用 rhGH 治疗出生的 SGA 儿童最终身高的预测因素。材料和方法：在这项在三级儿科内分泌转诊中心进行的回顾性研究中，我们招募了所有出生 SGA（定义为出生身长或体重 #x3c；第 10 个百分位）的患者接受 rhGH 治疗超过 12 个月，他们的最终身高数据可用。一些患者接受了促性腺激素释放激素 (GnRH) 类似物治疗。结果：我们纳入了 252 名平均出生身长为 -2.0 ± 0.7 SD 和出生体重为 -1.7 ± 1.0 SD 的患者。经过 4.6 ± 2.8 年的 rhGH 治疗，他们的身高从 -2.2 ± 0.9 SD 增加到 -1.5 ± 0.9 SD。在多变量分析中，我们确定了 8 个预测最终身高 46% 的因素，即 SGA 的原因 ( p #x3c; 0.0001)、GnRH 模拟疗法 #x3e；2 年 ( p = 0.006)、出生身长 ( p #x3c ; 0.02)、rhGH 开始时的身高 ( p #x3c; 0.0001)、rhGH 开始时的 IGF-1 水平 ( p = 0.0002)、治疗第一年的生长速度 ( p = 0.0002)，以及年龄和青春期开始时的身高 ( p #x3c; 0.0001, p= 0.0007，分别）。结论：在这一大群达到最终身高的 SGA 患者中，我们能够确认生长激素增加了矮 SGA 儿童的最终身高。此外，我们确定了与对生长激素治疗的更好反应相关的几个因素。
儿科研究